Clinical Trial Update: A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax [Phase 1, Phase 2]

View source ↗

Summary

A multi-site Phase 1/2 trial evaluating a three-drug regimen (tagraxofusp, azacitidine, and venetoclax) for measurable residual disease in acute myeloid leukemi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Leukemia

Drugs mentioned

• Azacitidine (Vidaza) (azacitidine)
• Tagraxofusp (Elzonris) (tagraxofusp)
• Venetoclax (Venclyxto) (venetoclax)

Snippet

Sponsor: Jacqueline Garcia, MD | Conditions: Acute Myeloid Leukaemia (AML), Leukemia | Phase 1, Phase 2 | Status: RECRUITING